Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8TC57
UPID:
M1AP_HUMAN
Alternative names:
Meiosis 1-arresting protein; Meiosis 1-associated protein; Spermatogenesis-associated protein 37
Alternative UPACC:
Q8TC57; B7Z6E7; E9PGG8; Q6ZP30; Q96L07
Background:
The Meiosis 1 arrest protein, also known as Meiosis 1-arresting protein, Meiosis 1-associated protein, and Spermatogenesis-associated protein 37, plays a crucial role in spermatogenesis. It is essential for meiosis I progression, a pivotal phase in the formation of sperm cells.
Therapeutic significance:
Linked to Spermatogenic failure 48, a disorder characterized by non-obstructive azoospermia due to spermatogenesis defects, this protein's dysfunction underscores its potential as a target for therapeutic intervention in male infertility.